ABION Inc. (KOSDAQ:203400)

Market Cap	173.26B
Revenue (ttm)	759.68M
Net Income (ttm)	-43.38B
Shares Out	28.64M
EPS (ttm)	-1,800.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,357
Average Volume	93,083
Open	5,880.00
Previous Close	5,870.00
Day's Range	5,880.00 - 6,100.00
52-Week Range	5,240.00 - 13,000.00
Beta	1.01
RSI	41.78
Earnings Date	May 15, 2025

About ABION

ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various re...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 203400

Financial Performance

In 2024, ABION's revenue was 759.68 million, a decrease of -40.38% compared to the previous year's 1.27 billion. Losses were -43.38 billion, 48.5% more than in 2023.